drugset / Trial / NCT06428500
QTX3046 in Patients With KRAS G12D Mutations
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Timeline
- Start
- 2024-05-30
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | QTX3046 | Unknown | — | Oral |